Serum levels of soluble Fas correlate with indices of organ damage in                 systemic lupus erythematosus

Al-Maini, Mustafa; Mountz, John D.; Al-Mohri, H; El-Ageb, El-Nour; Al-Riyami, Bazdawi M.; Svenson, Karin L. G.; Zhou, Tong; Richens, Elizabeth R.

doi:10.1191/096120300678828145

Cited by 37 publications

(35 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We extended these findings by demonstrating in children an association between sFas and sFasL with sepsis-induced liver failure and with SMOF, a liver failure-dependent categorization. FasL on infiltrating lymphocytes may also interact with hepatocyte Fas independent of the effect of circulating sFasL (25,34). Our autopsy results support a role for Fas in sepsisinduced liver injury, possibly mediated by hepatocyte lymphocyte infiltration.…”

Section: Discussionsupporting

confidence: 72%

“…This finding suggests that sFasL may have a different role compared with sFas in the children with severe septic shock. In agreement with adult studies, both sFasL and sFas levels were associated with liver failure and DIC (22)(23)(24)(25)(26)(33)(34)(35). Current literature suggests that sFasL may interact with hepatic Fas and induce liver injury, thereby inducing shedding of sFas (24,25,36).…”

Section: Discussionsupporting

confidence: 68%

See 1 more Smart Citation

sFas and sFas Ligand and Pediatric Sepsis-Induced Multiple Organ Failure Syndrome

et al. 2002

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 72%

Section: Discussionsupporting

confidence: 68%

sFas and sFas Ligand and Pediatric Sepsis-Induced Multiple Organ Failure Syndrome

et al. 2002

View full text Add to dashboard Cite

“…23 The enhanced serum levels of soluble Fas demonstrated that the intriguing effect of the Fas/FasL pathway on cell death was related to disease activity. [24][25][26] These findings indicate that in SLE patients, the Fas/ FasL pathway plays an important role in immune homeostasis and maintenance of self-tolerance. However, gene mutation in the coding regions of FasL rarely occurs in human lupus patients.…”

Section: Introductionmentioning

confidence: 87%

The −844C/T polymorphism in the Fas ligand promoter associates with Taiwanese SLE

Chen¹,

Wang²,

Chi³

et al. 2005

Genes Immun

View full text Add to dashboard Cite

FasL expression is critical in T-cell activation-induced apoptosis, which is involved in lupus pathogenesis. This study identified two SNPs in the FasL promoter regions from -1145 to -45 by genomic DNA sequencing. The -844C/T polymorphism was previously described by its location in and affect on the CCAAT/enhancer-binding protein b (C/EBPB b)-binding site and the other (-1094A/C, a novel polymorphism) was located at the NF-kB transcription-binding site. FasL gene promoter polymorphisms were genotyped in 260 systemic lupus erythematosus (SLE) patients and 280 healthy controls using MassArray matrix-assisted laser desorption ionization-time-of-flight (MALDI-TOF) mass spectrometry. The distribution of FasL promoter -844C/C genotype, predominant in Taiwanese, was skewed in Taiwanese SLE patients (odds ratio: 1.53; P-value ¼ 0.014). FasL promoter À844C/T polymorphism genotype distributions of Taiwanese, African Americans, and Caucasians differed. Moreover, no particular clinical association of À844C/T and À1094A/C polymorphisms with SLE was found in patients in Taiwan. This study confirmed that À844C/C genotype is associated with lupus susceptibility. The -1094A/C polymorphism is not significantly associated with lupus disease susceptibility, albeit the role of NF-kB pathway in FasL promoter activation remains unclear. Fas/FasL pathway may contribute to SLE polygenic disease entity.

show abstract

“…27 The levels of the soluble form of the Fas apoptosis antigen (sFas) were significantly higher in SLE patients than in healthy controls, and sFas levels correlated with organ damage, including ovary damage. 28 Regular menstrual periods are an easily ascertainable external parameter of intact ovarian function; however, the presence of regular bleeding is not synonymous with nonimpaired ovarian reserve. Lawrenz et al 29 found that in premenopausal SLE patients not receiving alkylating therapy, the AMH values were significantly lower compared to the control group.…”

Section: Figmentioning

confidence: 99%

Subclinical Impairment of Ovarian Reserve in Systemic Lupus Erythematosus Patients with Normal Menstruation Not Using Alkylating Therapy

Zhan

Liang

et al. 2013

Journal of Women's Health

View full text Add to dashboard Cite

Background: Disease activity is a major factor in menstrual disorders in systemic lupus erythematosus (SLE) patients not receiving alkylating therapy. However, the ovarian reserve of SLE women with normal menstruation is still unclear. Methods: Twenty-three SLE patients naïve to cytotoxic agents (SLE group) and nineteen SLE patients receiving current or previous cyclophosphamide (CTX) therapy (without other cytotoxic agents; SLE-CTX group) were enrolled. Twenty-one age-matched healthy women served as controls. All patients and controls had a regular menstrual cycle. Basal hormone levels, including follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E 2 ), and anti-Mü llerian hormone (AMH), and antral follicle count (AFC) were analyzed in the two study groups and compared with the control group. Results: No significant differences were found between the SLE, SLE-CTX, and control groups in age, body mass index (BMI), and basal FSH and LH levels. The E 2 (P = 0.023) levels were high and the AMH (P = 0.000) values and AFC (P = 0.001) were significantly lower in the SLE and SLE-CTX groups compared to control. However, these values were similar between the SLE and SLE-CTX groups. Conclusion: SLE patients not receiving alkylating therapy who had normal menstruation and short illness duration still had an impaired ovarian reserve.

show abstract

Serum levels of soluble Fas correlate with indices of organ damage in systemic lupus erythematosus

Abstract: sFas is elevated in sera of SLE patient. Since sFas correlates with indices of organ damage but not with disease activity, it may be a marker of organ damage in SLE and may act to protect certain organs from further damage by inhibiting Fas-mediated apoptosis.

Cited by 37 publications

References 37 publications

sFas and sFas Ligand and Pediatric Sepsis-Induced Multiple Organ Failure Syndrome

sFas and sFas Ligand and Pediatric Sepsis-Induced Multiple Organ Failure Syndrome

The −844C/T polymorphism in the Fas ligand promoter associates with Taiwanese SLE

Subclinical Impairment of Ovarian Reserve in Systemic Lupus Erythematosus Patients with Normal Menstruation Not Using Alkylating Therapy

Contact Info

Product

Resources

About